Core Viewpoint - MIRXES-B (02629) has seen a significant increase in stock price, rising over 8% to reach a new high of 47.8 HKD, following the announcement of a memorandum of understanding with PT DIASTIKA BIOTEKINDO for collaboration in the Indonesian market [1][2] Group 1 - The company’s indirect wholly-owned subsidiary, MiRXES PTE. LTD., has entered into a memorandum of understanding with PT DIASTIKA BIOTEKINDO to collaborate on molecular diagnostic testing and related instruments for early detection and diagnosis of high-incidence and high-mortality cancers in Indonesia [1][2] - The memorandum is valid for 12 months from the date of signing [1] - Through this partnership, the company aims to leverage PT DIASTIKA BIOTEKINDO's existing channels to deploy blood-based microRNA or multi-omics cancer detection devices in the Indonesian market [2] Group 2 - The collaboration will allow the company to benefit from Indonesia's localization policies, such as tax incentives for local content rates of 40% [2] - The partnership is expected to provide regulatory flexibility under the ASEAN-centered medical device framework [2] - Indonesia is viewed as a pilot region for the company to replicate its business model in Southeast Asia, the Middle East, North Africa, and other regions with similar cancer profiles and healthcare structures [2]
港股异动 | MIRXES-B(02629)涨超8%创新高 以部署基于血液microRNA等检测设备方式进军印尼市场